Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction (NCT00365157)
A Phase I/II Study of E7389 Halichondrin B Analog (NSC # 707389) in Metastatic Urothelial Tract Cancer and Renal Insufficiency
🩺 Plain-English Summary (8th-Grade Level)
This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue (locally advanced) or to other places in the body (metastatic)and kidney dysfunction. Drugs used in chemotherapy, such as eribulin mesylate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Chemotherapy drugs may have different effects in patients who have changes in their kidney function.
Who can join: Review the eligibility criteria below.
Location: Tower Cancer Research Foundation — Beverly Hills, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (26 Sites)
Showing the first 25 of 26 sites.
- Tower Cancer Research Foundation — Beverly Hills, California
- City of Hope Comprehensive Cancer Center — Duarte, California
- City of Hope Antelope Valley — Lancaster, California
- USC / Norris Comprehensive Cancer Center — Los Angeles, California
- Contra Costa Regional Medical Center — Martinez, California
- Veterans Administration Hospital - Martinez — Martinez, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- City of Hope South Pasadena — South Pasadena, California
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Decatur Memorial Hospital — Decatur, Illinois
- NorthShore University HealthSystem-Evanston Hospital — Evanston, Illinois
- Ingalls Memorial Hospital — Harvey, Illinois
- Duly Health and Care Joliet — Joliet, Illinois
- Loyola University Medical Center — Maywood, Illinois
- Illinois CancerCare-Peoria — Peoria, Illinois
- Central Illinois Hematology Oncology Center — Springfield, Illinois
- Southern Illinois University School of Medicine — Springfield, Illinois
- Fort Wayne Medical Oncology and Hematology Inc-Parkview — Fort Wayne, Indiana
- Community Howard Regional Health — Kokomo, Indiana
- Northern Indiana Cancer Research Consortium — South Bend, Indiana
- University of Michigan Comprehensive Cancer Center — Ann Arbor, Michigan
- Wayne State University/Karmanos Cancer Institute — Detroit, Michigan
- Oncology Care Associates PLLC — Saint Joseph, Michigan
- Mercy Hospital Saint Louis — St Louis, Missouri
- University of Pittsburgh Cancer Institute (UPCI) — Pittsburgh, Pennsylvania
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Advanced Urothelial Carcinoma
- A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma — San Francisco, California
- A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer — Long Beach, California
- Immunotherapy Plus Capivasertib for Metastatic Bladder Cancer — West Haven, Connecticut
Explore by condition: All Advanced Urothelial Carcinoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.